MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00259-024-07056-3

Медицинская библиотека · European journal of nuclear medicine and molecular imaging · 2025

An 211At-labeled alpha-melanocyte stimulating hormone peptide analog for targeted alpha therapy of metastatic melanoma.

Suzuki Hiroyuki, Yamashita Saki, Tanaka Shoko, Kannaka Kento, Sasaki Ichiro, Ohshima Yasuhiro, Watanabe Shigeki, Ooe Kazuhiro, Watabe Tadashi, Ishioka Noriko S, Tanaka Hiroshi, Uehara Tomoya

СтатьяПеревод пока не подготовлен

Аннотация

PURPOSE: Patients who develop metastatic melanoma have a very poor prognosis, and new treatments are needed to improve the response rates. Melanocortin-1 receptor (MC1R) is a promising target for radionuclide therapy of metastatic melanoma, and alpha-melanocyte stimulating hormone (α-MSH) peptide analogs show high affinities to MC1Rs. Because targeted alpha therapy (TAT) can be a desirable treatment for metastatic melanoma, this study aimed to develop an 211At-labeled α-MSH peptide analog for TAT of metastatic melanoma.

METHODS

We designed an α-MSH analog labeled with 211At using a neopentyl glycol scaffold via a hydrophilic linker. Preliminary studies using 125I-labeled α-MSH analogs were performed to identify suitable hydrophilic linkers. Then, [211At]NpG-GGN4c was prepared using a procedure similar to that of the 125I-labeled counterpart, [125I]NpG-GGN4b. The biodistribution profile of [211At]NpG-GGN4c in B16F10 tumor-bearing mice was compared with that of [125I]NpG-GGN4b. B16F10 tumor-bearing mice were treated with a single dose of vehicle or [211At]NpG-GGN4c (1 or 0.4 MBq).

RESULTS

The D-Glu-D-Arg linker was identified as the optimal hydrophilic linker because of its high affinity for MC1R and good biodistribution profile, especially with low accumulation in the liver and intestine. [211At]NpG-GGN4c showed tumor accumulation comparable to that of [125I]NpG-GGN4b and maintained the tumor radioactivity retention from 1 to 3 h postinjection. [211At]NpG-GGN4c exhibited a dose-dependent inhibitory effect on B16F10 xenograft growth without apparent body weight loss.

CONCLUSION

[211At]NpG-GGN4c showed dose-dependent efficacy against B16F10 xenografts, suggesting that [211At]NpG-GGN4c is a promising TAT agent for treating metastatic melanoma.

Для цитирования: Suzuki Hiroyuki, Yamashita Saki, Tanaka Shoko, Kannaka Kento, Sasaki Ichiro, Ohshima Yasuhiro, Watanabe Shigeki, Ooe Kazuhiro, Watabe Tadashi, Ishioka Noriko S, Tanaka Hiroshi, Uehara Tomoya. An 211At-labeled alpha-melanocyte stimulating hormone peptide analog for targeted alpha therapy of metastatic melanoma.. European journal of nuclear medicine and molecular imaging. 2025. DOI: 10.1007/s00259-024-07056-3.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.